Literature DB >> 25390062

Re-emergence of susceptibility to conventional first line drugs in Salmonella isolates from enteric fever patients in Nepal.

Hari Jung Chand1, Komal Raj Rijal, Biswas Neupane, Vijay Kumar Sharma, Bharat Jha.   

Abstract

INTRODUCTION: Enteric fever is endemic in Nepal and poses a significant public health burden. The first-line drugs ampicillin, chloramphenicol, and cotrimoxazole have not been part of empirical therapy for two decades due to the development of multidrug-resistant Salmonella strains. The objective of this study was to determine the antibiogram pattern of Salmonella serovars isolated from the blood of clinically suspected enteric fever patients.
METHODOLOGY: A cross sectional study was carried out in a tertiary care hospital in Lalitpur, Nepal, between July 2011 and February 2012. Standard microbiological procedures were followed during collection and processing of blood samples, isolation and identification of Salmonella serotypes. The antimicrobial sensitivity of ampicillin, chloramphenicol, cotrimoxazole, nalidixic acid, and ciprofloxacin was determined using a modified Kirby-Bauer disk diffusion method as per the guidelines of the Clinical and Laboratory Standards Institute.
RESULTS: Out of 86 Salmonella isolates, 56 (65.1%) were Salmonella Typhi and 30 (34.9%) were Salmonella Paratyphi A. Salmonella Typhi were 100% sensitive to chloramphenicol, cotrimoxazole, and ciprofloxacin and 98.2% sensitive to ampicillin. Similarly, Salmonella Paratyphi A isolates were 100% sensitive to ampicillin and cotrimoxazole and 96.7% sensitive to chloramphenicol and ciprofloxacin. More than 90.0% of isolates were nalidixic acid resistant and none of the Salmonella isolates were multi-drug resistant.
CONCLUSIONS: This study revealed the increasing frequency of nalidixic acid-resistant Salmonella isolates, indicating the possibility of fluoroquinolone resistance in near future. Furthermore, re-emergence of susceptibility to conventional first-line drugs ampicillin, chloramphenicol, and cotrimoxazole supports the possibility of using these drugs in empirical therapy.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25390062     DOI: 10.3855/jidc.4228

Source DB:  PubMed          Journal:  J Infect Dev Ctries        ISSN: 1972-2680            Impact factor:   0.968


  19 in total

1.  Cotrimoxazole treats fluoroquinolone-resistant Salmonella typhi H58 infection.

Authors:  Manan Karki; Sarbagya Pandit; Stephen Baker; Buddha Basnyat
Journal:  BMJ Case Rep       Date:  2016-10-26

2.  The Search for Effective Empiric Therapy for Acute Undifferentiated Febrile Illness.

Authors:  George M Varghese
Journal:  Clin Infect Dis       Date:  2021-10-05       Impact factor: 9.079

3.  Re-emergence of the susceptibility of the Salmonella spp. isolated from blood samples to conventional first line antibiotics.

Authors:  Krishma Laxmi Shrestha; Narayan Dutt Pant; Raju Bhandari; Sabita Khatri; Basudha Shrestha; Binod Lekhak
Journal:  Antimicrob Resist Infect Control       Date:  2016-05-25       Impact factor: 4.887

4.  A 23-year retrospective investigation of Salmonella Typhi and Salmonella Paratyphi isolated in a tertiary Kathmandu hospital.

Authors:  Raphaël M Zellweger; Buddha Basnyat; Poojan Shrestha; Krishna G Prajapati; Sabina Dongol; Paban K Sharma; Samir Koirala; Thomas C Darton; Christiane Dolecek; Corinne N Thompson; Guy E Thwaites; Stephen G Baker; Abhilasha Karkey
Journal:  PLoS Negl Trop Dis       Date:  2017-11-27

5.  Enteric Fever Caused by Salmonella enterica Serovars with Reduced Susceptibility of Fluoroquinolones at a Community Based Teaching Hospital of Nepal.

Authors:  Anjeela Bhetwal; Anjila Maharjan; Puspa Raj Khanal; Narayan Prasad Parajuli
Journal:  Int J Microbiol       Date:  2017-11-06

6.  Antimicrobial Resistance of Salmonella enterica Serovars Typhi and Paratyphi Isolates from a General Hospital in Karawaci, Tangerang, Indonesia: A Five-Year Review.

Authors:  Nata Pratama Hardjo Lugito
Journal:  Int J Microbiol       Date:  2017-04-06

7.  Open label comparative trial of mono versus dual antibiotic therapy for Typhoid Fever in adults.

Authors:  Niv Zmora; Sudeep Shrestha; Ami Neuberger; Yael Paran; Rajendra Tamrakar; Ashish Shrestha; Surendra K Madhup; T R S Bedi; Rajendra Koju; Eli Schwartz
Journal:  PLoS Negl Trop Dis       Date:  2018-04-23

8.  Trends in antibiotic susceptibility of enteric fever isolates from South India, 2002-2013.

Authors:  Sangeeta Joshi; Ranjeeta Adhikary; Hosdurg Bhaskar Beena; Malavalli Venkatesh Bhavana; Rajvir Bhalwar
Journal:  Med J Armed Forces India       Date:  2018-10-25

9.  Co-trimoxazole versus azithromycin for the treatment of undifferentiated febrile illness in Nepal: study protocol for a randomized controlled trial.

Authors:  Sunil Pokharel; Buddha Basnyat; Amit Arjyal; Saruna Pathak Mahat; Raj Kumar Kc; Abhusani Bhuju; Buddhi Poudyal; Evelyne Kestelyn; Ritu Shrestha; Dung Nguyen Thi Phuong; Rajkumar Thapa; Manan Karki; Sabina Dongol; Abhilasha Karkey; Marcel Wolbers; Stephen Baker; Guy Thwaites
Journal:  Trials       Date:  2017-10-02       Impact factor: 2.279

10.  Renaissance of Conventional First-Line Antibiotics in Salmonella enterica Clinical Isolates: Assessment of MICs for Therapeutic Antimicrobials in Enteric Fever Cases from Nepal.

Authors:  Puspa Raj Khanal; Deepa Satyal; Anjeela Bhetwal; Anjila Maharjan; Shreena Shakya; Snehika Tandukar; Narayan Prasad Parajuli
Journal:  Biomed Res Int       Date:  2017-09-05       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.